Literature DB >> 3105442

Characterization of impermeability variants of Pseudomonas aeruginosa isolated during unsuccessful therapy of experimental endocarditis.

A S Bayer, D C Norman, K S Kim.   

Abstract

We characterized five amikacin-resistant variants of Pseudomonas aeruginosa isolated from aortic valve vegetations during unsuccessful therapy of experimental endocarditis. These organisms were cross resistant to other aminoglycosides. No aminoglycoside-modifying enzymes were produced by these strains. However, all five variants demonstrated significant defects in permeability and intracellular uptake of [3H]amikacin when compared with the amikacin-susceptible parental strain (0 to 26% of that of the parental strain; mean, approximately 15%). The permeability defects were unstable in vitro, with normalization after serial passage in antibiotic-free media. The variants grew as nonpigmented, small-colony types, with in vitro generation times approximately 1.5 to 2 times longer than that of the parental strain (30 to 40 versus 20 min, respectively). Two impermeability variants were compared with the parental strain for ability to induce experimental endocarditis in rabbits with aortic catheters. Both variants were virulent in vivo; however, mean bacterial densities in vegetations were approximately 2.5 log10 CFU/g lower in animals challenged with the variants than in animals challenged with the parental strain, probably reflecting a slower in vivo growth rate.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3105442      PMCID: PMC174654          DOI: 10.1128/AAC.31.1.70

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  R-factor mediated gentamicin resistance: A new enzyme which modifies aminoglycoside antibiotics.

Authors:  R Benveniste; J Davies
Journal:  FEBS Lett       Date:  1971-05-20       Impact factor: 4.124

2.  Morphological expressions of antibiotic synergism against Pseudomonas aeruginosa as observed by scanning electron microscopy.

Authors:  S J Waisbren; D J Hurley; B A Waisbren
Journal:  Antimicrob Agents Chemother       Date:  1980-12       Impact factor: 5.191

Review 3.  Mechanisms of resistance to aminoglycosides in clinical isolates.

Authors:  K Shannon; I Phillips
Journal:  J Antimicrob Chemother       Date:  1982-02       Impact factor: 5.790

4.  Therapy of experimental Pseudomonas endocarditis with high-dose amikacin and ticarcillin.

Authors:  C Choi; A S Bayer; N K Fujita; K Lam; L B Guze; T T Yoshikawa
Journal:  Chemotherapy       Date:  1983       Impact factor: 2.544

5.  Efficacy of amikacin and ceftazidime in experimental aortic valve endocarditis due to Pseudomonas aeruginosa.

Authors:  A S Bayer; D Norman; K S Kim
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

6.  Endocarditis due to methicillin-resistant Staphylococcus aureus in rabbits: expression of resistance to beta-lactam antibiotics in vivo and in vitro.

Authors:  H F Chambers; C J Hackbarth; T A Drake; M G Rusnak; M A Sande
Journal:  J Infect Dis       Date:  1984-06       Impact factor: 5.226

7.  Current problems in the treatment of infective endocarditis due to Pseudomonas aeruginosa.

Authors:  M P Reyes; A M Lerner
Journal:  Rev Infect Dis       Date:  1983 Mar-Apr

8.  Amikacin + ceftazidime therapy of experimental right-sided Pseudomonas aeruginosa endocarditis in rabbits.

Authors:  A S Bayer; K Lam; D Norman; K S Kim; J O Morrison
Journal:  Chemotherapy       Date:  1985       Impact factor: 2.544

9.  Outbreak of endocarditis caused by Pseudomonas aeruginosa serotype O11 among pentazocine and tripelennamine abusers in Chicago.

Authors:  R Shekar; T W Rice; C H Zierdt; C A Kallick
Journal:  J Infect Dis       Date:  1985-02       Impact factor: 5.226

10.  Lipopolysaccharide changes in impermeability-type aminoglycoside resistance in Pseudomonas aeruginosa.

Authors:  L E Bryan; K O'Hara; S Wong
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

View more
  7 in total

1.  In vitro characterization of aminoglycoside adaptive resistance in Pseudomonas aeruginosa.

Authors:  J A Karlowsky; M H Saunders; G A Harding; D J Hoban; G G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

2.  Interaction of gentamicin with the A band and B band lipopolysaccharides of Pseudomonas aeruginosa and its possible lethal effect.

Authors:  J L Kadurugamuwa; J S Lam; T J Beveridge
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

3.  Chronic prosthetic hip infection caused by a small-colony variant of Escherichia coli.

Authors:  A Roggenkamp; A Sing; M Hornef; U Brunner; I B Autenrieth; J Heesemann
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

4.  Phenotypic variation of Staphylococcus epidermidis in infection of transvenous endocardial pacemaker electrodes.

Authors:  L M Baddour; L P Barker; G D Christensen; J T Parisi; W A Simpson
Journal:  J Clin Microbiol       Date:  1990-04       Impact factor: 5.948

5.  Efficacy of ceftazidime and aztreonam alone or in combination with amikacin in experimental left-sided Pseudomonas aeruginosa endocarditis.

Authors:  A Pefanis; H Giamarellou; P Karayiannakos; I Donta
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

6.  MexXY-OprM efflux pump is necessary for a adaptive resistance of Pseudomonas aeruginosa to aminoglycosides.

Authors:  Didier Hocquet; Christelle Vogne; Farid El Garch; Anne Vejux; Naomasa Gotoh; Angela Lee; Olga Lomovskaya; Patrick Plésiat
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

7.  Bactericidal interactions of a beta-lactam and beta-lactamase inhibitors in experimental Pseudomonas aeruginosa endocarditis caused by a constitutive overproducer of type Id beta-lactamase.

Authors:  A S Bayer; M Selecky; K Babel; L Hirano; J Yih; T R Parr
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.